Baucus and Grassley say the FDA suppresses scientific dissent

Share this article:
Sens. Max Baucus (D-MT) and Chuck Grassley (R-IA) say the FDA continues to suppress scientific dissent and punish agency staff who raise safety issues. In a letter to the FDA commissioner, the senators say an unnamed senior FDA official has been sidelined after voicing concerns about the safety of GlaxoSmithKline's diabetes drug Avandia.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.